

# Impact evaluation

## of the MOTION FOR A RESOLUTION

pursuant to Rule 111(3) of the Rules of Procedure on the Commission delegated regulation of 26 May 2021 supplementing Regulation (EU) 2019/6 of the European Parliament and of the Council by establishing the **criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans** (C(2021)03552 – 2021/2718(DEA))





Committee on the Environment, Public Health and Food Safety  
Member responsible: Martin Häusling

12th July 2021




# Impact of the motion > ban of 191 antibiotics for veterinary use (for a total of 596 Antibiotic Marketing Authorizations in France => 32%)


Antimicrobials  
for humans only




- Gram negative infections (*E. coli*) (i.e. bovine mastitis, enteritis, septicemia or respiratory diseases in poultry) could no longer be treated.



- Very limited therapeutical possibilities in bovine & porcine respiratory diseases.
- Very high risk of antimicrobial resistance.



- Many companion animals infections possibly lifethreatening (like pneumonia, pyometra, peritonitis, pleuritis & skin diseases) could no longer be treated.



- Many bacterial infections in horses, small mammals, reptiles & exotic animals could no longer be treated.